Monopar Therapeutics short interest in 2022
In 2022, Monopar Therapeutics's disclosed short interest ran from 0.16% of shares outstanding on 14 Jan 2022 to 0.21% on 15 Dec 2022, a change of +0.05 percentage points. The year's high was 0.32% on 30 Nov 2022 and its low 0.02% on 15 Mar 2022, averaging 0.10% across 19 twice-monthly settlement dates. FINRA's days-to-cover figure peaked at 2.55 days on 30 Nov 2022. Full history: Monopar Therapeutics.
Cite this page
By year: 2020 · 2021 · 2022 · 2023 · 2024 · 2025 · 2026
2022 in figures
- Start of year
- 0.16% (14 Jan 2022)
- End of year
- 0.21% (15 Dec 2022)
- Change
- +0.05 pp
- High
- 0.32% (30 Nov 2022)
- Low
- 0.02% (15 Mar 2022)
- Average
- 0.10%
- Highest days to cover
- 2.55 (30 Nov 2022)
- SEC filings marked
- 8
Every report in 2022
| Settlement | Short interest | Days to cover | Filings since previous |
|---|---|---|---|
| 14 Jan 2022 | 0.16% | 1.00 | |
| 31 Jan 2022 | 0.14% | 2.01 | |
| 15 Mar 2022 | 0.02% | 1.00 | |
| 31 Mar 2022 | 0.05% | 1.00 | 10-K filed, results (8-K) |
| 14 Apr 2022 | 0.02% | 1.79 | |
| 29 Apr 2022 | 0.03% | 1.00 | |
| 13 May 2022 | 0.02% | 1.00 | 10-Q filed, results (8-K) |
| 15 Jun 2022 | 0.05% | 1.00 | |
| 30 Jun 2022 | 0.06% | 1.00 | |
| 15 Jul 2022 | 0.05% | 1.70 | |
| 29 Jul 2022 | 0.07% | 1.05 | |
| 31 Aug 2022 | 0.06% | 1.16 | 10-Q filed, results (8-K) |
| 15 Sep 2022 | 0.09% | 1.00 | |
| 30 Sep 2022 | 0.14% | 1.88 | |
| 14 Oct 2022 | 0.09% | 1.00 | |
| 31 Oct 2022 | 0.13% | 2.33 | |
| 15 Nov 2022 | 0.25% | 1.00 | 10-Q filed, results (8-K) |
| 30 Nov 2022 | 0.32% | 2.55 | |
| 15 Dec 2022 | 0.21% | 1.00 |
See also: Monopar Therapeutics's full history · most shorted US stocks of 2022 · today's US league.
About this data
US short interest data: FINRA (finra.org), shown as reported shares short divided by SEC-reported shares outstanding for each settlement date. FINRA® is a registered trademark of the Financial Industry Regulatory Authority, Inc. This site is not affiliated with or endorsed by FINRA or the SEC; displayed for personal reference, bulk redistribution is not permitted (see terms). Nothing here is investment advice. Method: methodology.